Moderna creates COO role, brings back Juan Andres as Jerh Collins retires

Moderna, Inc. announced on September 30, 2026 that it created a new Chief Operating Officer position and named Juan Andres to fill it, effective October 5, 2026, according to an 8-K filing. In the newly created role, Andres will support the increasing scale and diversification of the company and will report to Chief Executive Officer Stephane Bancel while serving on the Executive Committee.¹

The company said the new role comes as Moderna prepares for the potential launch and scale-up of intismeran autogene following positive Phase 3 results and continues to advance a broader oncology portfolio.¹ Moderna added that it has also expanded its infectious disease franchise, which now includes five approved vaccines following the recent U.S. FDA approval of its seasonal flu vaccine and European Commission marketing authorization of its seasonal flu plus COVID combination vaccine.¹ The filing notes intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.¹

Andres, age 62, is returning to the company. He previously spent nearly six years at Moderna, including serving as its Chief Technical Operations and Quality Officer from 2018 through 2022 and as its President, Strategic Partnerships and Enterprise Expansion before retiring from Moderna in 2023.¹

Under his offer letter dated September 3, 2026, Andres will receive an initial annual base salary of $800,000 and will be eligible for an annual cash bonus, commencing with a pro-rated bonus for 2026, with an annual incentive target of 90% of his base salary.¹ He will also receive a new hire equity award valued at a total of $5,000,000, subject to a four-year vesting period.¹

Separately, Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, will retire from the company.¹ Collins joined Moderna in October 2022 and became Chief Technical Operations and Quality Officer in January 2023.¹